L3VLUP
ProSign in

MRNA · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MRNAARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MRNA
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterMRNAARGX
Q3 20206 holders, $3.1bn8 holders, $3.6bn
Q4 202016 holders, $4.4bn7 holders, $4.1bn
Q1 202118 holders, $8.0bn8 holders, $4.1bn
Q2 202122 holders, $18.4bn9 holders, $4.6bn
Q3 202127 holders, $27.6bn8 holders, $4.5bn
Q4 202120 holders, $17.2bn9 holders, $5.3bn
Q1 202216 holders, $11.8bn8 holders, $5.3bn
Q2 202219 holders, $10.2bn13 holders, $6.5bn
Q3 202222 holders, $8.4bn14 holders, $5.3bn
Q4 202220 holders, $13.0bn13 holders, $5.5bn
Q1 202317 holders, $11.2bn13 holders, $5.9bn
Q2 202315 holders, $8.9bn18 holders, $6.6bn
Q3 202312 holders, $7.2bn21 holders, $8.7bn
Q4 20238 holders, $6.9bn17 holders, $6.3bn
Q1 20247 holders, $7.6bn13 holders, $6.8bn
Q2 202413 holders, $9.5bn14 holders, $7.9bn
Q3 202412 holders, $4.8bn13 holders, $10.7bn
Q4 202415 holders, $3.1bn14 holders, $12.3bn
Q1 202511 holders, $2.0bn17 holders, $11.8bn
Q2 202510 holders, $2.0bn18 holders, $10.8bn
Q3 20259 holders, $1.2bn16 holders, $13.8bn
Q4 202510 holders, $2.5bn16 holders, $14.8bn
Q1 20269 holders, $4.8bn11 holders, $12.3bn
Q2 20269 holders, $8.0bn14 holders, $15.0bn
MRNA

Moderna Inc

Holders
12
Reported value
$4.8bn
Buyers
9
Sellers
4

Breadth +5 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
13
Reported value
$10.7bn
Buyers
7
Sellers
7

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2024

Among the 22 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MRNA (9)

ARK Investment Management LLC, Baillie Gifford & Co, Invesco Ltd, PDT Partners LLC, Squarepoint Ops LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC

Only ARGX (10)

Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., ExodusPoint Capital Management LP, Holocene Advisors LP, Janus Henderson Group Ltd, Marshall Wace LLP, Moore Capital Management LP, T. Rowe Price Associates Inc

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →